Anti-LC-1 antibody or antigen binding fragment thereof, preparation method and application

By developing recombinant anti-LC-1 antibodies or antigen-binding fragments thereof, the problem of insufficient specificity and affinity of anti-LC-1 antibodies in the prior art has been solved, and efficient diagnosis and monitoring of autoimmune hepatitis type II and other diseases has been achieved.

CN119504992AActive Publication Date: 2025-02-25ZHUHAI LIHE MEDICAL DIAGNOSTIC PROD CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411728749.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-11-28
Publication Date
2025-02-25
Estimated Expiration
2044-11-28

AI Technical Summary

Technical Problem

The existing anti-LC-1 antibody detection methods have problems with insufficient specificity and affinity, and it is difficult to effectively assist in the diagnosis and monitoring of autoimmune hepatitis type II and other diseases.

Method used

A recombinant anti-LC-1 antibody or antigen-binding fragment thereof, containing variable regions of heavy and light chains, is developed, and is expressed in cells through gene recombination technology, achieving high affinity-specific binding to LC-1 antigen.

Benefits of technology

This antibody or its antigen-binding fragment has good affinity and specificity, can effectively bind LC-1 antigen, is used for disease diagnosis and monitoring, and has a simple production process and good stability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119504992A_ABST
    Figure CN119504992A_ABST
Patent Text Reader

Abstract

The invention provides an anti-LC-1 antibody or an antigen binding fragment thereof, a preparation method and application, and relates to the technical field of biology. The anti-LC-1 antibody or the antigen binding fragment thereof contains a complementarity determining region of a heavy chain variable region and a complementarity determining region of a light chain variable region, wherein the complementarity determining region of the heavy chain variable region comprises amino acid sequences consistent with VH-CDR1, VH-CDR2 and VH-CDR3 of the heavy chain variable region as shown in SEQ ID NO.1; the complementarity determining region of the light chain variable region comprises amino acid sequences which are consistent with the amino acid sequences of VL-CDR1, VL-CDR2 and VL-CDR3 of the light chain variable region as shown in SEQ ID NO.2. The anti-LC-1 antibody or the antigen binding fragment thereof has good specific binding capacity with the LC-1 antigen, and can be used for identification of the anti-LC-1 antibody or the LC-1 antigen and auxiliary diagnosis and detection of positive diseases of the anti-LC-1 antibody.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of antibody technology, and in particular to an anti-LC-1 antibody or an antigen-binding fragment thereof, a preparation method and an application thereof. Background Art

[0002] The following statements merely provide background information related to the present disclosure and do not necessarily constitute prior art.

[0003] Anti-hepatocyte cytoplasmic type I antibodies (anti-LC-1 antibodies) are considered to be another marker antibody for type II AIH (autoimmune hepatitis). In 1988, Martini et al. first confirmed the presence of anti-LC-1 antibodies in the sera of 6 adult autoimmune hepatitis patients using IIF and ID methods. The target antigen exists in the cytoplasm of hepatocytes, and its components are fomiminotransferase cyclodeaminase and argininosuccinate lyase. The IB method detects hepatocyte cytoplasmic polypeptide proteins of 58-62kD. The detection of anti-LC-1 antibodies is of great significance for the diagnosis and typing of AIH.

[0004] Anti-LC-1 antibody is a serum-specific antibody for autoimmune hepatitis type II, with a positive rate of 56% to 72%. Clinically, anti-LC-1 antibody is more common in young AIH patients under 20 years old, but less common in AIH patients over 40 years old. Anti-LC-1 antibody often coexists with anti-LKM-1 antibody. Among patients with positive anti-LC-1 antibody, 32% to 67% can detect anti-liver and kidney microsomal antibodies (anti-LKM-1 antibody); among patients with positive anti-LKM-1 antibody, 25% to 50% can detect anti-LC-1 antibody. Therefore, anti-LC-1 antibody and anti-LKM-1 antibody are closely related. Hepatitis C virus (HCV) infection is not related to LC-1, and anti-HCV and anti-LC-1 antibodies do not cross-react. Therefore, the specificity of anti-LC-1 antibody for AIH is better than that of anti-LKM-1 antibody. Anti-LC-1 antibodies are correlated with the disease activity of AIH-II and are a marker of disease activity and a prognostic indicator for AIH.

[0005] Therefore, the development of high-affinity anti-LC-1 recombinant monoclonal antibodies is of great significance and value for the development of clinical detection kits.

[0006] In view of this, the present invention is proposed. Summary of the invention

[0007] The object of the present invention is to provide an anti-LC-1 antibody or an antigen-binding fragment thereof, which has good specific binding ability with the LC-1 antigen. Based on the anti-LC-1 antibody or antigen-binding fragment thereof provided by the present invention, the object of the present invention is also to provide its use. Another object of the present invention is to develop an anti-LC-1 antibody or antigen-binding fragment thereof with good binding activity in a simpler method, which can be used for the identification of the LC-1 antigen, and to assist in the diagnosis or auxiliary diagnosis of anti-LC-1 antibody positive diseases.

[0008] In order to solve the above technical problems, the present invention particularly adopts the following technical solutions:

[0009] Definition of terms:

[0010] The "LC-1 antigen" in this article refers to the antigen that can be bound by natural anti-LC-1 antibodies (anti-hepatocyte cytoplasmic type I antibodies). These antigens are usually present in the cytoplasm of hepatocytes. Their components are fomiminotransferase cyclodeaminase and argininosuccinate lyase. The IB method detects them as 58-62kD hepatocyte cytoplasmic polypeptide proteins.

[0011] The "anti-LC-1 antibody or antigen-binding fragment thereof" herein refers to a molecule that can specifically bind to the above-mentioned "LC-1 antigen".

[0012] The term "antibody or antigen-binding fragment thereof" herein refers to all proteins and protein fragments comprising a complementary determining region (CDR region). Proteins and protein fragments may be antibodies, and the terms "antibody" and "full-length antibody" include polyclonal antibodies and monoclonal antibodies. In addition, the term "antibody" includes naturally occurring antibodies as well as non-naturally occurring antibodies, including, for example, chimeric, bifunctional and humanized antibodies, and related synthetic isoforms. Non-naturally occurring antibodies are also referred to herein as "recombinant antibodies," and the term "antibody" can be used interchangeably with "immunoglobulin." Proteins and protein fragments may be or may be antigen-binding fragments comprising part or all of the antibody CDR, which lack at least some of the amino acids present in the full-length chain of the antibody but are still able to specifically bind to the antigen. Such fragments are biologically active because they bind to the target antigen and can compete with other antigen-binding molecules (including intact antibodies) for binding to a given epitope. Such fragments are selected from, but not limited to, any one of F(ab')2, Fab', Fab, Fv (composed of VH and VL), ScFv (single-chain antibody, VH and VL are connected by a connecting peptide), dsFv (disulfide-stabilized Fv antibody (dsFv)), bispecific antibodies, nanobodies, and antibody minimum recognition units. In addition to the above functional fragments, any fragments with increased half-life are also included.

[0013] The term "variable region" or "variable domain" refers to the domain of the amino terminus of the heavy chain or light chain of an antibody that recognizes and binds to an antigen. The composition and arrangement of the amino acids in this segment determine the specificity of the antibody in recognizing an antigen. The heavy chain variable domain may be referred to as "VH". The variable domain of the light chain may be referred to as "VL". These domains are usually the most variable parts of an antibody and contain antigen binding sites. The variable regions of the heavy and light chains are each composed of three complementarity-determining regions (CDRs) (also known as hypervariable regions) connected by four framework regions (FRs). The extent of the framework region and CDR has been precisely defined, for example, in Kabat (see Sequences of Proteins of Immunological Interest, E. Kabat et al.) and Chothia. Any CDR determination method well known in the art, including a combination of methods, can identify the CDRs of the variable domain. The CDRs in each chain are held together closely by FRs to form the variable region. Generally, the variable regions VL / VH of the heavy and light chains can be obtained by arranging and connecting the following numbered CDRs and FRs in the following combinations: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.

[0014] The term "constant region" or "constant domain" refers to the constant region of an antibody light chain or the constant region of an antibody heavy chain, either alone or in combination. The heavy chain of an antibody has one variable domain (VH), followed by a number of constant domains or regions, such as one or more of hinge, CH1, CH2, CH3 and CH4, the CH1 domain being adjacent to the VH domain and at the amino terminus of the hinge region of the antibody heavy chain, and not forming part of the Fc region of the antibody; the hinge region includes the portion of the heavy chain molecule that connects the CH1 domain to the CH2 domain; the N-terminus of CH2 is usually the CH3 domain, which usually forms the C-terminal portion of the antibody, and in some antibody types, such as IgM and IgE, the constant region also includes the CH4 domain. The constant region of an antibody can be derived from IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE and IgD, as well as subclasses and mutant forms of the constant regions thereof.

[0015] The present invention does not limit the method of obtaining the anti-LC-1 antibody or its antigen-binding fragment. In some optional embodiments, the polynucleotide encoding the anti-LC-1 antibody or its antigen-binding fragment is connected to a vector and then expressed in a cell to obtain the corresponding antibody. The above-mentioned vector can be introduced into eukaryotic cells, especially mammalian cells, to construct and obtain the anti-LC-1 antibody or its antigen-binding fragment that can express it. In other optional embodiments, the anti-LC-1 antibody or its antigen-binding fragment can also be obtained by recombinant genetics techniques known to those skilled in the art or by peptide synthesis, such as an automatic peptide synthesizer (for example, an automatic peptide synthesizer sold by Applied BioSystems, etc.); the antigen-binding fragment can also be optionally produced by enzymatic cleavage of the antigen-binding molecule (including the whole antibody), such as pepsin or papain cleavage; or chemical cleavage, such as obtaining the above-mentioned antigen-binding fragment by chemical reduction splitting disulfide bonds.

[0016] The terms "specific recognition", "selective binding", "selectively binds" and "specifically binds" or similar expressions refer to the binding of an antibody or its antigen-binding fragment to a predetermined epitope on an antigen. -5 M, for example, less than about 10 -5 M, 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M or 10 -10 M or smaller K d The K value of an antibody can be determined using methods well established in the art. d Other standard assays for evaluating the binding ability of a ligand, such as an antibody, to a target are known in the art and include, for example, ELISA, Western blot, RIA, and flow cytometry analysis.

[0017] The binding ability of anti-LC-1 antibodies or antigen-binding fragments thereof to the target antigen can also be expressed as "half-maximal effective concentration (EC50)", which refers to the concentration of the drug or antibody that can achieve 50% of the maximum biological effect after a specific exposure time. Generally, the smaller the EC50, the better the affinity, indicating that it can bind to the target protein at a lower concentration. The EC50 value can be determined by binding assays known in the art, such as direct or indirect binding assays (e.g., enzyme-linked immunosorbent assay (ELISA), flow cytometric fluorescence sorting technology, and other binding assays).

[0018] The term "signal substance" herein refers to a substance that can provide a detectable signal, which can be directly observed by the naked eye or detected by conventional instruments acceptable in the art; the signal substance can directly provide a signal, such as color (such as colloidal gold, colored microspheres), fluorescence (fluorescent molecules), magnetism, radiation or luminescence; it can also provide a signal indirectly through a subsequent reaction in which the signal substance participates, such as catalyzing a specific substrate reaction to produce any of the above signals.

[0019] The term "polynucleotide" herein refers to a polymeric form of nucleotides of any length, including ribonucleotides and / or deoxyribonucleotides. Examples of polynucleotides include, but are not limited to, single-stranded, double-stranded or multi-stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids, or polymers containing purine and pyrimidine bases or other natural, chemically or biochemically modified, non-natural or derived nucleotide bases. The polynucleotide encodes the above-mentioned anti-LC-1 antibody or antigen-binding fragment thereof, and the encoding is optionally encoding the sense strand or the antisense strand. The polynucleotide may be naturally occurring, synthetic, recombinant, or any combination thereof. The terms "polynucleotide" and "nucleic acid" are used interchangeably herein.

[0020] The term "vector" as used herein refers to a nucleic acid delivery vehicle into which a polynucleotide can be inserted. When a vector can express a protein encoded by the inserted polynucleotide, the vector is called an expression vector. A vector can be introduced into a cell by transformation, transduction or transfection so that the genetic material elements it carries are expressed in the cell.

[0021] The vector is well known to those skilled in the art, including but not limited to: plasmid, episomal plasmid, minicircle DNA, phagemid, cosmid; artificial chromosome, such as yeast artificial chromosome (YAC), bacterial artificial chromosome (BAC) or P1-derived artificial chromosome (PAC); bacteriophage such as λ phage or M13 phage and animal virus, etc. Animal viruses that can be used as vectors include but are not limited to retrovirus (including lentivirus), adenovirus, adeno-associated virus, herpes virus (such as herpes simplex virus), poxvirus, baculovirus, papillomavirus, papillomavirus. In some embodiments, the vector of the present invention contains regulatory elements commonly used in genetic engineering, such as enhancers, promoters, internal ribosome entry sites (IRES) and other expression control elements (such as transcription termination signals, or polyadenylation signals and poly-U sequences, etc.).

[0022] As used herein, the expressions "cell", "cell line" and "cell culture" are used interchangeably, and all such designations include progeny. Progeny may not necessarily be identical to the original cell due to natural, accidental or deliberate mutation, and may differ from the original cell in morphology and / or in genomic DNA. "Transformants" and "transformed cells" include the primary subject cell and cultures derived therefrom.

[0023] As used herein, the term "purified" or "isolated" in connection with a polypeptide or nucleic acid means that the polypeptide or nucleic acid is not in its natural medium or natural form. Thus, the term "isolated" includes a polypeptide or nucleic acid removed from its original environment, such as if it is naturally present, from its natural environment. For example, an isolated polypeptide is generally free of at least some proteins or other cellular components that are normally associated with it or are normally mixed with it or in solution. Isolated polypeptides include naturally produced polypeptides contained in cell lysates, polypeptides in purified or partially purified form, recombinant polypeptides, polypeptides expressed or secreted by cells, and polypeptides in heterologous cells or cultures. In connection with nucleic acids, the term isolated or purified indicates, for example, that the nucleic acid is not in its natural genomic context (e.g., in a vector, as an expression cassette, connected to a promoter, or artificially introduced into a heterologous cell).

[0024] The term "anti-LC-1 antibody-positive disease" as used herein refers to a disease that can cause the patient's anti-LC-1 antibody level to be higher than that of a patient without the disease. Exemplary anti-LC-1 antibody-positive diseases include, but are not limited to, type II autoimmune hepatitis.

[0025] In this document, unless otherwise stated, arbitrary numbering is used to distinguish one entity or behavior from another entity or behavior, and does not necessarily require or imply any actual relationship, order, or importance between these entities or behaviors, such as numbers (I), (II)...(V).

[0026] As used herein, unless otherwise stated, "optionally", "optional", "optional" or "optional" means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs or does not occur.

[0027] Herein, the terms "comprise" or "comprising" are intended to include stated elements, integers or steps, but not to exclude any other elements, integers or steps.

[0028] In a first aspect, an anti-LC-1 antibody or an antigen-binding fragment thereof is provided, which comprises a heavy chain variable region and a light chain variable region.

[0029] The heavy chain variable region includes complementary determining regions VH-CDR1, VH-CDR2 and VH-CDR3; the light chain variable region includes complementary determining regions VL-CDR1, VL-CDR2 and VL-CDR3;

[0030] The VH-CDR1 includes an amino acid sequence consistent with VH-CDR1 of the heavy chain variable region shown in SEQ ID NO.1, the VH-CDR2 includes an amino acid sequence consistent with VH-CDR2 of the heavy chain variable region shown in SEQ ID NO.1, and the VH-CDR3 includes an amino acid sequence consistent with VH-CDR3 of the heavy chain variable region shown in SEQ ID NO.1; and, the VL-CDR1 includes an amino acid sequence consistent with VL-CDR1 of the light chain variable region shown in SEQ ID NO.2, the VL-CDR2 includes an amino acid sequence consistent with VL-CDR2 of the light chain variable region shown in SEQ ID NO.2, and the VL-CDR3 includes an amino acid sequence consistent with VL-CDR3 of the light chain variable region shown in SEQ ID NO.2.

[0031] It is understood that the amino acid sequences of other regions except the CDR region in the variable region shown in SEQ ID NO.1 or 2 are not used to limit the anti-LC-1 antibody or antigen-binding fragment thereof provided by the present invention. For example, if the anti-LC-1 antibody or antigen-binding fragment thereof provided by the present application contains a framework region, it may be different from the framework region in the variable region shown in SEQ ID NO.1 or 2. The CDR region in the variable region shown in SEQ ID NO.1 or 2 can be divided according to an optional method known in the art. Optionally, VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2 and VL-CDR3 of the variable region are defined by any one of the systems of Kabat, Chothia, IMGT, ABM or Contact or a combination of multiple definition systems. Taking the Kabat, Chothia, IMGT, ABM or Contact definitions as examples, the amino acid sequences of VH-CDR1, VH-CDR2 and VH-CDR3 of the heavy chain variable region shown in SEQ ID NO.1 and the amino acid sequences of VL-CDR1, VL-CDR2 and VL-CDR3 of the light chain variable region shown in SEQ ID NO.2 are shown in Table 1:

[0032] Table 1

[0033]

[0034] In an optional embodiment, the anti-LC-1 antibody or antigen-binding fragment thereof has VH-CDR1, VH-CDR2 and VH-CDR3 of the heavy chain variable region defined in Table 1, and VL-CDR1, VL-CDR2 and VL-CDR3 of the light chain variable region defined in Table 1. Taking the IMGT definition as an example: the amino acid sequence of the VH-CDR1 is shown in SEQ ID NO.11, the amino acid sequence of the VH-CDR2 is shown in SEQ ID NO.16, and the amino acid sequence of the VH-CDR3 is shown in SEQ ID NO.19; the amino acid sequence of the VL-CDR1 is shown in SEQ ID NO.22, the amino acid sequence of the VL-CDR2 is QMS, and the amino acid sequence of the VL-CDR3 is shown in SEQ ID NO.25.

[0035] In an optional embodiment, the heavy chain variable region further contains at least one framework region, such as one framework region, two framework regions, three framework regions or four framework regions.

[0036] In an alternative embodiment, the light chain variable region further comprises at least one framework region, such as one framework region, two framework regions, three framework regions or four framework regions.

[0037] In an optional embodiment, the species origin of each of the framework regions independently includes, but is not limited to, one or more of rabbits, cows, horses, dairy cows, pigs, sheep, goats, rats, mice, dogs, cats, camels, donkeys, deer, minks, chickens, ducks, geese, turkeys, fighting cocks, humans, and their mutants.

[0038] In an optional embodiment, the framework region VH-FR1 of the heavy chain variable region includes an amino acid sequence consistent with VH-FR1 of the heavy chain variable region shown in SEQ ID NO.1; and / or the framework region VH-FR2 includes an amino acid sequence consistent with VH-FR2 of the heavy chain variable region shown in SEQ ID NO.1; and / or the framework region VH-FR3 includes an amino acid sequence consistent with VH-FR3 of the heavy chain variable region shown in SEQ ID NO.1; and / or the framework region VH-FR4 includes an amino acid sequence consistent with VH-FR4 of the heavy chain variable region shown in SEQ ID NO.1.

[0039] In an optional embodiment, the framework region VL-FR1 of the light chain variable region includes an amino acid sequence consistent with VL-FR1 of the light chain variable region shown in SEQ ID NO.2; and / or the framework region VL-FR2 includes an amino acid sequence consistent with VL-FR2 of the light chain variable region shown in SEQ ID NO.2; and / or the framework region VL-FR3 includes an amino acid sequence consistent with VL-FR3 of the light chain variable region shown in SEQ ID NO.2; and / or the framework region VL-FR4 includes an amino acid sequence consistent with VL-FR4 of the light chain variable region shown in SEQ ID NO.2.

[0040] In an optional embodiment, the amino acid sequence of the heavy chain variable region of the anti-LC-1 antibody or antigen-binding fragment thereof is shown in SEQ ID NO.1, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO.2.

[0041] In an alternative embodiment, the anti-LC-1 antibody or antigen-binding fragment thereof is an antibody or antigen-binding fragment comprising a constant region.

[0042] In an alternative embodiment, at least a portion of the constant region sequence of the anti-LC-1 antibody or antigen-binding fragment thereof is a human constant region sequence.

[0043] In an optional embodiment, the constant region sequence of the anti-LC-1 antibody or its antigen-binding fragment is selected from the sequence of a portion or all of the constant region of any one of IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE or IgD, wherein the IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE or IgD include their subclasses and mutant forms.

[0044] In an alternative embodiment, the anti-LC-1 antibody or antigen-binding fragment thereof contains a heavy chain constant region.

[0045] In an optional embodiment, the heavy chain constant region sequence of the anti-LC-1 antibody or antigen-binding fragment thereof is selected from a portion or all of the constant region sequence of human IgG1, preferably including CH1, CH2 and CH3 of the constant region of human IgG1.

[0046] In an optional embodiment, the amino acid sequence of the heavy chain constant region is shown in SEQ ID NO.3.

[0047] In an alternative embodiment, the anti-LC-1 antibody or antigen-binding fragment thereof contains a light chain constant region.

[0048] In an optional embodiment, the light chain constant region sequence is selected from the light chain constant region of a mouse.

[0049] In an optional embodiment, the amino acid sequence of the light chain constant region is shown in SEQ ID NO.4.

[0050] In an optional embodiment, the anti-LC-1 antibody or its antigen-binding fragment is a human-mouse chimeric antibody, the heavy chain amino acid sequence of the anti-LC-1 antibody or its antigen-binding fragment is shown in SEQ ID NO.5, and the light chain amino acid sequence is shown in SEQ ID NO.6.

[0051] In a second aspect, a biomaterial is also provided, comprising a polynucleotide, a vector or a cell; wherein the polynucleotide encodes the above-mentioned anti-LC-1 antibody or its antigen-binding fragment; the vector carries the polynucleotide; the cell carries the polynucleotide, or contains the vector or is capable of expressing the anti-LC-1 antibody or its antigen-binding fragment.

[0052] After the polynucleotide encoding the anti-LC-1 antibody or its antigen-binding fragment is connected to the vector, the above-mentioned vector can be introduced into eukaryotic cells, especially mammalian cells, to construct a cell line capable of expressing the anti-LC-1 antibody or its antigen-binding fragment, and the corresponding protein can be obtained by cell expression.

[0053] In an optional embodiment, the cells used to express the anti-LC-1 antibody or antigen-binding fragment thereof are 293 cells (human kidney epithelial cell line), preferably 293F cells.

[0054] In an alternative embodiment, the cell used to express the anti-LC-1 antibody or antigen-binding fragment thereof is a CHO cell (Chinese Hamster Ovary cell).

[0055] In a third aspect, a method for preparing the anti-LC-1 antibody or antigen-binding fragment thereof of the first aspect is provided, comprising culturing cells capable of expressing the anti-LC-1 antibody or antigen-binding fragment thereof.

[0056] In an optional embodiment, the preparation method further comprises transforming the polynucleotide encoding the anti-LC-1 antibody or antigen-binding fragment thereof into cells and expressing the polynucleotide, and obtaining the anti-LC-1 antibody or antigen-binding fragment thereof by purification.

[0057] In an optional embodiment, the preparation method further comprises synthesizing a polynucleotide containing a gene encoding the anti-LC-1 antibody or its antigen-binding fragment as needed, and / or preparing a suitable expression vector as needed, transforming the expression vector into a desired cell and expressing it, and obtaining the anti-LC-1 antibody or its antigen-binding fragment by purification.

[0058] In an optional embodiment, the cell is obtained by transforming a polynucleotide encoding the anti-LC-1 antibody or antigen-binding fragment thereof as described in the first aspect into the cell, the polynucleotide comprises a heavy chain expression plasmid and a light chain expression plasmid, and the transformation comprises co-transforming the heavy chain expression plasmid and the light chain expression plasmid into the cell.

[0059] In an optional embodiment, the constant region fragment is fused to the C-terminus of the heavy chain variable region to construct a complete heavy chain expression plasmid.

[0060] In an optional embodiment, the constant region fragment includes one or more of CH1, CH2 and CH3, preferably includes CH1, CH2 and CH3.

[0061] In an optional embodiment, the cell is a eukaryotic cell, preferably a mammalian cell.

[0062] In an optional embodiment, the mammalian cells include 293 cells or CHO cells, preferably 293F cells.

[0063] In a fourth aspect, there is also provided use of the anti-LC-1 antibody or antigen-binding fragment thereof of the first aspect, or the biomaterial of the second aspect in any one of the following (I) to (VII):

[0064] (I) Detection of anti-LC-1 antibodies for non-diagnostic and therapeutic purposes;

[0065] (II) preparing products for detecting anti-LC-1 antibodies;

[0066] (III) Preparation of products for diagnosis and / or auxiliary diagnosis of anti-LC-1 antibody positive diseases;

[0067] (IV) Detection of LC-1 antigen for non-diagnostic and therapeutic purposes;

[0068] (V) preparing a product for detecting LC-1 antigen;

[0069] (VI) for separating, enriching and / or purifying LC-1 antigen;

[0070] (VII) preparing products for separation, enrichment and / or purification of LC-1 antigens;

[0071] In the applications of aspects (I) to (III) above, the anti-LC-1 antibody or its antigen-binding fragment can be used as a standard and / or quality control substance during detection to provide a reliable reference for the detection results, and can also be used to construct a standard curve.

[0072] In an optional embodiment, the anti-LC-1 antibody-positive disease includes type II autoimmune hepatitis.

[0073] The applications of aspects (IV) to (VII) above can utilize the ability of anti-LC-1 antibodies or antigen-binding fragments thereof to specifically target and bind to LC-1 antigens to achieve detection, separation, enrichment and / or purification of LC-1 antigens. In an optional embodiment, when the anti-LC-1 antibody or antigen-binding fragment thereof is an immunoconjugate, for example, connected to a signal substance, the localization or real-time detection of the LC-1 antigen can be achieved by detecting the signal substance. In an optional embodiment, the detection, separation, enrichment and / or purification of the LC-1 antigen is achieved by separating the anti-LC-1 antibody-LC-1 antigen immune complex.

[0074] In an optional embodiment, in the above aspects (II), (III), (V) or (VII), a person skilled in the art can prepare a corresponding product (such as the above-mentioned immunoconjugate) according to actual use, and select other reagents in the product, including but not limited to one or more of a signal substance, a solid phase carrier, a buffer reagent, a salt, a secondary antibody, a chromogenic substrate, a blocking solution, a washing solution, a solvent, an eluent, a coupling agent, a negative control, a positive control, a standard, a quality control product and a marker.

[0075] In a fifth aspect, a reagent or a kit is also provided, wherein the reagent or the kit comprises the anti-LC-1 antibody or antigen-binding fragment thereof according to the first aspect, or the biological material according to the second aspect.

[0076] In an optional embodiment, the kit is used to detect anti-LC-1 antibodies or anti-LC-1 antibody-positive diseases; the kit includes standards and / or quality controls, and the standards and / or quality controls contain the anti-LC-1 antibodies or antigen-binding fragments thereof.

[0077] In an optional embodiment, the kit is used to detect type II autoimmune hepatitis.

[0078] In an optional embodiment, the kit further comprises a detection reagent, and the detection reagent comprises an anti-LC-1 antibody detection reagent.

[0079] In an optional embodiment, the kit further comprises a detection reagent for detecting anti-LKM-1 antibodies.

[0080] In an optional embodiment, the kit further comprises a solid phase carrier.

[0081] In an optional embodiment, the anti-LC-1 antibody or antigen-binding fragment thereof in the reagent or kit is coupled to a solid phase carrier; or the anti-LC-1 antibody or antigen-binding fragment thereof in the reagent or kit is packaged separately from the solid phase carrier. By coupling the anti-LC-1 antibody or antigen-binding fragment thereof to a solid phase carrier, it can be used to capture the LC-1 antigen in the sample to be tested. Alternatively, by coupling the anti-LC-1 antibody or antigen-binding fragment thereof to a solid phase carrier, it can be used to purify the LC-1 antigen.

[0082] In an optional embodiment, the anti-LC-1 antibody detection reagent includes a solid phase carrier coupled to an LC-1 antigen.

[0083] In an optional embodiment, the kit further comprises a signal substance.

[0084] In an optional embodiment, the anti-LC-1 antibody or antigen-binding fragment thereof in the reagent or kit is coupled to a signal substance; or the anti-LC-1 antibody or antigen-binding fragment thereof in the reagent or kit and the signal substance are packaged separately. By coupling the anti-LC-1 antibody or antigen-binding fragment thereof to a signal substance, it can be used to locate and detect LC-1 antigen or detect LC-1 antigen in a sample by Western blotting.

[0085] The above reagents or kits may also optionally include reagents and / or consumables used in the art for detection reactions or protein purification, which are well known to those skilled in the art, including but not limited to one or more of buffer reagents, salts, secondary antibodies, chromogenic substrates, blocking solutions, washing solutions, solvents, eluents, coupling agents, negative controls, positive controls, standards, quality control products and markers.

[0086] The above reagents or kits can be used in general immunoassay methods acceptable in the art, including but not limited to immunofluorescence staining, flow sorting, immunoblotting, immunohistochemistry, ELISA, immunochromatography or immunomagnetic beads. Those skilled in the art can prepare reagents or other reagents in the kit according to the corresponding detection means, and the present invention is not limited to this.

[0087] The signal substance in any of the above embodiments includes, but is not limited to, one or more of enzymes, luminescent labels, fluorescent microspheres, colored microspheres, latex microspheres, colloidal gold, quantum dots, biotin, streptavidin, radionuclides, radiocontrast agents, paramagnetic ions, metals and photosensitizers.

[0088] Examples of enzymes include, but are not limited to, alkaline phosphatase or horseradish peroxidase. Examples of luminescent markers include, but are not limited to, fluorescent proteins, synthetic small molecules or polymer dyes, and specific examples include, but are not limited to, Alexa350, Alexa 405, Alexa430, Alexa 488, Alexa 555, Alexa 647, AMCA, aminoacridine, BODIPY630 / 650, BODIPY 650 / 665, BODIPY-FL, BODIPY-R6G, BODIPY-TMR, BODIPY-TRX, 5-carboxy-4′,5′-dichloro-2′,7′-dimethoxyfluorescein, 5-carboxy-2′,4′,5′,7′-tetrachlorofluorescein, 5-carboxyfluorescein, 5-carboxyrhodamine, 6-carboxyrhodamine, 6-carboxytetramethylrhodamine, Cascade Blue, Cy2, Cy3, Cy5, Cy7, 6-FAM, dansyl chloride, fluorescein, HEX, 6-JOE, NBD (7-nitrobenzo-2-oxa-1,3-diazole), Oregon Green 488, Oregon Green 500, Oregon Green514, Pacific Blue, phthalic acid, terephthalic acid, isophthalic acid, cresol fast violet, cresol blue violet, brilliant cresol blue, p-aminobenzoic acid, erythrosine, phthalocyanine, azomethine, cyanine, xanthine, succinylfluorescein, rare earth metal cryptates, trisbipyridyl diamine europium, europium cryptates or chelates, diamines, bicyanines, La Jolla blue dye, allophycocyanin, allococyanin One or more of B, phycocyanin C, phycocyanin R, thiamine, phycoerythrin, phycoerythrin R, REG, rhodamine green, rhodamine isothiocyanate, rhodamine red, ROX, TAMRA, TET, TRIT (tetramethylrhodamine isothiol), tetramethylrhodamine and Texas Red. Fluorescent microspheres, colored microspheres and latex microspheres are independently selected from products acceptable in the art, such as commercially available products. Radionuclides include but are not limited to 110 In, 111 In, 177 Lu, 18 F. 52 Fe, 62 Cu, 64 Cu, 67 Cu, 67 Ga, 68 Ga, 86 Y. 90 Y. 89 Zr, 94 mTc, 94 Tc, 99 mTc, 120 I.123 I. 124 I. 125 I. 131 I. 154-158 Gd, 32 P. 11 C. 13 N. 15 O. 186 Re, 188 Re, 51 Mn, 52 mMn, 55 Co. 72 As, 75 Br, 76 Br, 82 mRb and 83 Paramagnetic ions include, but are not limited to, one or more of chromium (III), manganese (II), iron (III), iron (II), cobalt (II), nickel (II), copper (II), neodymium (III), samarium (III), ytterbium (III), gadolinium (III), vanadium (II), terbium (III), dysprosium (III), holmium (III) and erbium (III).

[0089] The solid phase carrier in any of the above embodiments includes but is not limited to microtubes, columns, microparticles, nitrocellulose membranes, chromatography matrices or lateral flow devices; more specifically, for example, but not limited to, enzyme-labeled wells, immunochromatographic test strips or magnetic beads. The chromatography matrix can be any known chromatography matrix acceptable in the art, including but not limited to polystyrene, polysaccharide polymers or silica gel. In an optional embodiment, the chromatography matrix includes gel particles.

[0090] The present invention discloses an anti-LC-1 antibody or an antigen-binding fragment thereof, and further prepares a human-mouse chimeric recombinant monoclonal antibody. The present invention has the following beneficial effects:

[0091] (1) This method prepares anti-LC-1 antibodies or antigen-binding fragments with known sequences, can be recombinantly expressed in vitro, is simple to operate, takes a short time, has a controllable production process, and has small batch-to-batch differences. It also has the advantages of good stability. After treatment at 4°C for 7 days, the retention rate is greater than 95%, and after treatment at 37°C for 7 days, the retention rate is above 85%. It has a good application prospect.

[0092] (2) The antibodies of the present invention have good affinity, with EC50 of 1.42 nM and 2.63 nM, respectively, and can specifically bind to LC-1 antigen. They can be used for LC-1 antigen detection, including but not limited to the use of liquid phase chips, immunofluorescence staining, flow sorting, fluorescent microspheres and other technologies to identify LC-1 antigens; the anti-LC-1 antibody or its antigen-binding fragment can also be coupled to a chromatographic matrix for immunoaffinity chromatography purification of LC-1 antigens to improve the purity of the antigen.

[0093] (3) The anti-LC-1 antibody or its antigen-binding fragment can be used for anti-LC-1 antibody detection, antibodies in anti-LC1 antibody-positive disease diagnosis products (such as auxiliary diagnosis products for autoimmune hepatitis type II), for example, as quality control products and / or standard products for anti-LC-1 antibody detection products; when the anti-LC-1 antibody or its antigen-binding fragment is used as a quality control product in a test kit, it can alleviate the problems of cumbersome immune polyclonal antibody operation and low subsequent coupling efficiency; it can reduce production costs, stabilize product quality, and significantly improve reaction values; on the other hand, compared with the direct use of human serum, it can also avoid the problems of difficult sample sources and high costs. BRIEF DESCRIPTION OF THE DRAWINGS

[0094] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0095] Figure 1 The results of the ELISA assay for the binding of the recombinant monoclonal antibody Ab01-LC-1 to the LC-1 antigen in Example 2, Ab01-LC-1 is the binding activity of the recombinant monoclonal antibody Ab01-LC-1 to the LC-1 antigen, and Ab-BSA is the nonspecific binding activity of the recombinant monoclonal antibody Ab01-LC-1 to the control protein BSA;

[0096] Figure 2 The results of the ELISA assay for the binding of the recombinant monoclonal antibody Ab02-LC-1 to the LC-1 antigen in Example 2, Ab02-LC-1 is the binding activity of the recombinant monoclonal antibody Ab02-LC-1 to the LC-1 antigen, and Ab-BSA is the nonspecific binding activity of the recombinant monoclonal antibody Ab02-LC-1 to the control protein BSA;

[0097] Figure 3 This is the SDS-PAGE protein electrophoresis diagram of the recombinant monoclonal antibody Ab01-LC-1. M stands for Marker. Reducing stands for the reducing SDS-PAGE electrophoresis result of the recombinant monoclonal antibody Ab01-LC-1. The heavy chain and light chain are 50kDa and 25kDa, respectively. Non-reducing stands for the non-reducing SDS-PAGE electrophoresis result of the recombinant monoclonal antibody Ab01-LC-1. The size is about 150kDa. DETAILED DESCRIPTION

[0098] The technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments. Obviously, the described embodiments are part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0099] Example 1 Preparation of LC-1 chimeric antibody

[0100] Phage display technology was used to screen and obtain LC-1 specific high-affinity monoclonal strains. The Fab region sequence was obtained after sequencing and then gene synthesis was performed. The synthesized light chain gene and heavy chain gene were constructed separately on the vector PTT5.

[0101] The light chain gene is a complete mouse light chain, wherein the light chain constant region is shown in SEQ ID NO.4; the heavy chain gene is a heavy chain variable region (VH) C-terminus fused with a human IgG1 constant region fragment (including CH1-CH2-CH3) to construct a complete IgG heavy chain, wherein the heavy chain constant region is shown in SEQ ID NO.3. Two clones with better screening results were selected for sequencing, and two different LC-1 antibody sequences Ab01-LC-1 and Ab02-LC-1 were obtained by sequencing.

[0102] The constructed heavy chain gene expression plasmid and light chain gene expression plasmid were mixed with PEI at a molar ratio of 1:2 and then transfected into 293F suspension cells in the logarithmic growth phase. The cells were cultured in a shaking incubator at 37°C and 120 rpm. After 5 days, the cell supernatant was collected, the antibody was purified with Protein A, eluted with 0.1M Glycine (pH3.0), and neutralized by adding 1M Tris (pH8.0). After the elution was completed, the ultrafiltration centrifuge tube was replaced with PBS buffer and concentrated, and the protein concentration was determined.

[0103] Example 2 ELISA determination of the binding activity of recombinant monoclonal antibodies to LC-1 antigen

[0104] (1) LC-1 protein (reference sequence NP_996848.1, 2 μg / mL) was coated on an ELISA plate and BSA was coated as a nonspecific binding control and incubated at 4°C overnight.

[0105] (2) Discard the coating solution, wash the plate with PBST, pat dry, add 3% milk, and block at 37°C for 2 h.

[0106] (3) Discard the blocking solution, wash the plate with PBST, pat dry, add 1 μM starting antibody in 3-fold serial dilutions, and incubate at 37°C for 1.5 h.

[0107] (4) Discard the primary antibody, wash the plate with PBST, pat dry, add horseradish peroxidase (HRP)-labeled mouse anti-human IgG secondary antibody, and incubate at 37°C for 1 h.

[0108] (5) Discard the secondary antibody, wash the plate with PBST, pat dry, add the colorimetric substrate for color development, add the stop solution after 15 min to stop the reaction, and measure the OD value with an enzyme-labeled instrument.

[0109] (6) A nonlinear fitting plot was performed with the OD value as the ordinate and the logarithm of the antibody molar concentration as the abscissa.

[0110] like Figure 1 and Figure 2 As shown, the EC50 values ​​of the two antibodies were 1.42 nM (Ab01-LC-1) and 2.63 nM (Ab02-LC-1), respectively.

[0111] Example 3 Stability of LC-1 recombinant monoclonal antibody

[0112] After the LC-1 humanized antibody prepared in Example 1 was diluted to 2 mg / mL, it was diluted 1000 times with this concentration as the initial concentration, and placed at -80°C, 4°C and 37°C for 7 days, and the magnetic barcode coupled with the LC-1 antigen was detected by the fully automatic multiple immunoassay analyzer of Zhuhai Livzon Reagent Co., Ltd. The test results are shown in Table 2.

[0113] Table 2. Signal retention after thermal acceleration of antibodies

[0114]

[0115] It can be seen from Table 2 that after the antibody was diluted 1000 times and treated at 4°C for 7 days, the signal retention rates were 97.8% and 93%, respectively. After being treated at 37°C for 7 days, the signal retention rates were 88.2% and 85.9%, respectively. In summary, the stability of Ab01-LC-1 antibody is better.

[0116] Example 4 Sequence information of LC-1 recombinant monoclonal antibody Ab01-LC-1

[0117] The SDS-PAGE image of recombinant monoclonal antibody Ab01-LC-1 is as follows Figure 3 The heavy chain variable region sequence is shown in SEQ ID NO.1, and the light chain variable region sequence is shown in SEQ ID NO.2; the heavy chain constant region sequence is shown in SEQ ID NO.3, which is a human sequence, and the light chain constant region sequence is shown in SEQ ID NO.4, which is a mouse sequence. The complete heavy chain sequence is shown in SEQ ID NO.5, and the complete light chain sequence is shown in SEQ ID NO.6. The CDR sequence information is shown in Table 1.

[0118] Heavy chain variable region (SEQ ID NO.1)

[0119] QVQLQQSGNELVKPGSSVILSCKASGFTFTNYDINWVRQRPEQGLEWIGWIFPGDGHTRYNEK FKGKATLTMDKSSNTAYMQLSRLaseDSAVYFCAREYDHFDYWGQGTTLTVSS

[0120] Light chain variable region (SEQ ID NO.2)

[0121] DIVMTQAAFSNPVTLGTSASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLASGVP DRFSGSGSGTEFTLRISRVEAEDVGVYYCGQNLEVPLTFGAGTKLELK

[0122] Table 1

[0123]

[0124] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. An anti-LC-1 antibody or an antigen-binding fragment thereof, characterized in that comprising a heavy chain variable region and a light chain variable region; The heavy chain variable region includes complementary determining regions VH-CDR1, VH-CDR2 and VH-CDR3; the light chain variable region includes complementary determining regions VL-CDR1, VL-CDR2 and VL-CDR3; The VH-CDR1, VH-CDR2 and VH-CDR3 include amino acid sequences consistent with VH-CDR1, VH-CDR2 and VH-CDR3 of the heavy chain variable region shown in SEQ ID NO.1; the VL-CDR1, VL-CDR2 and VL-CDR3 include amino acid sequences consistent with VL-CDR1, VL-CDR2 and VL-CDR3 of the light chain variable region shown in SEQ ID NO.

2.

2. The anti-LC-1 antibody or antigen-binding fragment thereof according to claim 1, characterized in that: The VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2 and VL-CDR3 of the anti-LC-1 antibody or antigen-binding fragment thereof are defined by any one of the Kabat, Chothia, IMGT, ABM or Contact systems or a combination of multiple definition systems; Optionally, according to the IMGT definition: the amino acid sequence of the VH-CDR1 is shown in SEQ ID NO.11, the amino acid sequence of the VH-CDR2 is shown in SEQ ID NO.16, and the amino acid sequence of the VH-CDR3 is shown in SEQ ID NO.19; The amino acid sequence of the VL-CDR1 is shown in SEQ ID NO.22, the amino acid sequence of the VL-CDR2 is QMS, and the amino acid sequence of the VL-CDR3 is shown in SEQ ID NO.

25.

3. The anti-LC-1 antibody or antigen-binding fragment thereof according to claim 1, characterized in that: The heavy chain variable region further comprises a framework region, and / or the light chain variable region further comprises a framework region; Optionally, the species origin of each of the framework regions independently includes, but is not limited to, one or more of rabbit, cattle, horse, dairy cow, pig, sheep, goat, rat, mouse, dog, cat, camel, donkey, deer, mink, chicken, duck, goose, turkey, fighting cock, human and their mutants; Optionally, at least one framework region of the heavy chain variable region comprises an amino acid sequence consistent with the framework region of the heavy chain variable region shown in SEQ ID NO.1; Optionally, at least one framework region of the light chain variable region comprises an amino acid sequence consistent with the framework region of the light chain variable region shown in SEQ ID NO.2; Optionally, the amino acid sequence of the heavy chain variable region of the anti-LC-1 antibody or antigen-binding fragment thereof is as shown in SEQ ID NO.1, and the amino acid sequence of the light chain variable region is as shown in SEQ ID NO.

2.

4. The anti-LC-1 antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, characterized in that: The anti-LC-1 antibody or antigen-binding fragment thereof is a complete antibody, F(ab')2, Fab', Fab, Fv, scFv, dsFv, bispecific antibody or antibody minimum recognition unit; Optionally, the species from which the remaining sequences of the antibody minus the CDR region originate include one or more of mice, rats, guinea pigs, hamsters, rabbits, ferrets, cats, dogs, goats, sheep, cows, pigs, horses, monkeys and humans.

5. The anti-LC-1 antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, characterized in that: It also contains a constant region; Optionally, at least a portion of the constant region sequence is a human constant region sequence; Optionally, the constant region sequence is selected from a sequence of a partial or complete constant region of any one of IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE or IgD; Optionally, the anti-LC-1 antibody or antigen-binding fragment thereof contains a heavy chain constant region, and the heavy chain constant region sequence is selected from a human heavy chain constant region; Optionally, the amino acid sequence of the heavy chain constant region is shown in SEQ ID NO.3; Optionally, the anti-LC-1 antibody or antigen-binding fragment thereof contains a light chain constant region; Optionally, the light chain constant region sequence is selected from a mouse light chain constant region, and the amino acid sequence of the light chain constant region is shown in SEQ ID NO.4; Optionally, the anti-LC-1 antibody or antigen-binding fragment thereof is a complete antibody, the heavy chain amino acid sequence is shown in SEQ ID NO.5, and the light chain amino acid sequence is shown in SEQ ID NO.

6.

6. Biomaterial, characterized in that including a polynucleotide, a vector or a cell; The polynucleotide encodes the anti-LC-1 antibody or antigen-binding fragment thereof according to any one of claims 1 to 5; The vector carries the polynucleotide; The cell carries the polynucleotide, or contains the vector, or is capable of expressing the anti-LC-1 antibody or antigen-binding fragment thereof according to any one of claims 1 to 5.

7. The method for preparing the anti-LC-1 antibody or antigen-binding fragment thereof according to any one of claims 1 to 5, characterized in that: Comprising culturing the cell as claimed in claim 6; Optionally, the cell is obtained by transforming a polynucleotide encoding an anti-LC-1 antibody or an antigen-binding fragment thereof according to any one of claims 1 to 5 into a cell, wherein the polynucleotide comprises a heavy chain expression plasmid and a light chain expression plasmid, and the transformation comprises co-transforming the heavy chain expression plasmid and the light chain expression plasmid into the cell; Optionally, the cell is a eukaryotic cell, preferably a mammalian cell; Optionally, the mammalian cells include 293 cells or CHO cells, preferably 293F cells.

8. Use of the anti-LC-1 antibody or antigen-binding fragment thereof according to any one of claims 1 to 5, or the biomaterial according to claim 6 in any one of the following (I) to (VII): (I) Detection of anti-LC-1 antibodies for non-diagnostic and therapeutic purposes; (II) preparing products for detecting anti-LC-1 antibodies; (III) Preparation of products for diagnosis and / or auxiliary diagnosis of anti-LC-1 antibody positive diseases; (IV) Detection of LC-1 antigen for non-diagnostic and therapeutic purposes; (V) preparing a product for detecting LC-1 antigen; (VI) for separating, enriching and / or purifying LC-1 antigen; (VII) preparing products for separation, enrichment and / or purification of LC-1 antigens; Optionally, the anti-LC-1 antibody-positive disease includes type II autoimmune hepatitis; Optionally, in any one of (I) to (III), the anti-LC-1 antibody or antigen-binding fragment thereof is used as a standard or quality control substance.

9. A reagent or a kit, characterized in that The reagent or kit comprises the anti-LC-1 antibody or antigen-binding fragment thereof according to any one of claims 1 to 5, or the biomaterial according to claim 6.

10. The reagent or kit according to claim 9, characterized in that The kit is used for detecting anti-LC-1 antibodies or anti-LC-1 antibody-positive diseases; the kit comprises a standard substance and / or a quality control substance, and the standard substance and / or the quality control substance contain the anti-LC-1 antibody or an antigen-binding fragment thereof; Optionally, the kit further comprises an anti-LC-1 antibody detection reagent; Optionally, the kit further comprises a detection reagent for detecting anti-LKM-1 antibodies.

Citation Information

Patent Citations

  • Kit for detecting LC-1 antibody relative to autoimmune liver diseases, and detection method with kit

    CN102955027A

  • KK-LC-1 targeted binding protein and derivative, kit and application thereof

    CN117700493A

  • PCNA binding protein, preparation method and application

    CN118909110A

  • Method and kit for predicting expression of KK-LC-1 in stomach cancer cell

    JP2020020649A